Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(10):723; doi:10.1093/jnci/96.10.723-b
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

© 2004 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Chemotherapeutic Drugs and Trastuzumab, In Vitro and In Vivo

Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2. By using multiple drug effect/combination index isobologram analysis, Pegram et al. (p. 739) characterized interactions between trastuzumab and several chemotherapeutic agents commonly used in the treatment of breast cancer. The authors found that, at a wide range of clinically achievable drug concentrations, carboplatin, 4-hydroxycyclophosphamide, docetaxel, and vinorelbine each interacted synergistically with trastuzumab in four breast cancer cell lines, whereas doxorubicin, epirubicin, and paclitaxel each interacted additively. The authors also observed a synergistic interaction with . . . [Full Text of this Article]

Increasing Colorectal Cancer Screening

Adjuvant Chemotherapy Delivery in Colon Cancer

Hodgkin Lymphoma and Multiple Sclerosis

Factors Influencing Melanoma Risk